Log in to your Inderes Free account to see all free content on this page.
Qlucore
0.51 SEK
+0.80 %
Less than 1K followers
QCORE
First North Stockholm
IT Services
Technology
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.80 %
+15.00 %
+9.52 %
+1.61 %
+1.20 %
-41.40 %
-92.68 %
-
-98.19 %
Qlucore develops AI-based software for use in the healthcare sector. The company's precision medicine solutions transform genetic data into decision-making data to create the right treatment for patients. The company's first diagnostic test – for blood cancer in children – has been approved and CE-marked. The company also has tests for lung cancer under development, and is developing the Qlucore Omics Explorer analysis software.
Read moreMarket cap
21.71M SEK
Turnover
10.53K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28.5.
2026
Annual report '26
10.9.
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
Qlucore Launches AI-based test for Acute Myeloid Leukemia
Interim report 1 May 2025 - 31 January 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio